aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 3.91 USD -1.51%
Market Cap: 328.2m USD
Have any thoughts about
aTyr Pharma Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

-3.9
Current
-2.3
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.9
=
Enterprise Value
263.2m USD
/
EBIT
-68.1m USD
All Countries
Close
Market Cap EV/EBIT
US
aTyr Pharma Inc
NASDAQ:ATYR
328.2m USD -3.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -218 012.9
US
Abbvie Inc
NYSE:ABBV
315.6B USD 23.8
US
Amgen Inc
NASDAQ:AMGN
140.4B USD 30.2
US
Gilead Sciences Inc
NASDAQ:GILD
113.3B USD 10
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 22.7
US
Epizyme Inc
F:EPE
94.1B EUR -498.7
AU
CSL Ltd
ASX:CSL
138.1B AUD 25.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.2B USD 17.4
US
Seagen Inc
F:SGT
39.3B EUR -52.8
NL
argenx SE
XBRU:ARGX
37.3B EUR -106.3
EBIT Growth EV/EBIT to Growth
US
aTyr Pharma Inc
NASDAQ:ATYR
Average EV/EBIT: 21.5
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 012.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.2
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -498.7 N/A N/A
AU
CSL Ltd
ASX:CSL
25.1
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
12%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -106.3 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-3.7
2-Years Forward
EV/EBIT
-3.6
3-Years Forward
EV/EBIT
-4